Gevo Insider Exercise and 10b5-1 Sales Reported by Director

Rhea-AI Filing Summary

Amorelli Angelo, a director of Gevo, Inc. (GEVO), reported stock option exercise and subsequent open-market sales. On 08/12/2025 the reporting person acquired 100,000 shares by exercising options at an exercise price of $0.67 per share. That same day the filing shows sales of 183,515 shares reported under a 10b5-1 plan at a weighted average price of $1.9484 per share, and on 08/13/2025 an additional 16,485 shares were sold at a weighted average price of $2.00 per share. After these transactions the reporting person beneficially owned 124,639 derivative-backed shares and 2,942 to 202,942 common shares depending on the line item reported in the filing.

Positive

• Reported exercise of options: 100,000 shares acquired at an exercise price of $0.67 on 08/12/2025.
• Sales were executed pursuant to a documented 10b5-1 trading plan adopted 12/03/2024, as disclosed in the filing.

Negative

• Open-market dispositions: 183,515 shares sold on 08/12/2025 at a weighted average price of $1.9484 per share.
• Additional disposition: 16,485 shares sold on 08/13/2025 at a weighted average price of $2.00 per share.
• After the transactions the reporting person’s direct common stock holdings reported on lines vary, showing potential reductions in direct beneficial ownership (e.g., down to 2,942 shares on one line).

Insights

Financial Analyst

TL;DR Insider exercised options for 100,000 shares then sold ~200,000 shares under a 10b5-1 plan, showing material insider liquidity.

The filing documents option exercise at $0.67 for 100,000 shares on 08/12/2025 and multiple open-market sales totaling 200,000 shares across 08/12/2025 and 08/13/2025 at weighted average prices of $1.9484 and $2.00 respectively. These are explicit, reportable transactions that change the reporting person’s outstanding direct and derivative holdings and represent observable insider liquidity rather than an operational development for the issuer.

Corporate Governance Expert

TL;DR Transactions were executed under a documented 10b5-1 plan and reported on Form 4, meeting standard disclosure practices.

The filer states the sales were effected pursuant to a 10b5-1 trading plan adopted 12/03/2024 and provides weighted average sale prices and ranges. The Form 4 includes an attorney-in-fact signature and required explanatory footnotes. From a governance and disclosure perspective the filing contains the expected details for insider option exercise and programmed sales.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Amorelli Angelo

(Last) (First) (Middle)

C/O GEVO, INC. 345 INVERNESS DRIVE SOUTH

BUILDING C, SUITE 310

(Street)

ENGLEWOOD CO 80112

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Gevo, Inc. [ GEVO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/12/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/12/2025		M		100,000	A	$0.67	202,942	D
Common Stock	08/12/2025		S(1)		183,515	D	$1.9484(2)	19,427	D
Common Stock	08/13/2025		S		16,485	D	$2(3)	2,942	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$0.67	08/12/2025		M			100,000	05/23/2025	05/22/2034	Common Stock	100,000	$0	124,639	D

Explanation of Responses:

1. The reported transactions were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on December 3, 2024.

2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.8750 to $2.0200 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.0000 to $2.0010 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

	/s/ E. Cabell Massey, Attorney-in-Fact	08/15/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transactions did GEVO insider Amorelli Angelo report on Form 4?

The filing reports an option exercise of 100,000 shares at $0.67 on 08/12/2025 and open-market sales of 183,515 shares on 08/12/2025 and 16,485 shares on 08/13/2025.

Were the sales by Amorelli Angelo part of a 10b5-1 plan?

Yes. The filing states the reported transactions were effected pursuant to a 10b5-1 trading plan adopted on 12/03/2024.

At what prices were the GEVO shares sold according to the Form 4?

Sales on 08/12/2025 were at a weighted average price of $1.9484 per share (range $1.8750–$2.0200) and sales on 08/13/2025 were at a weighted average price of $2.00 per share (range $2.0000–$2.0010).

How many shares did the reporting person beneficially own after the reported transactions?

The filing shows 124,639 derivative-backed shares beneficially owned and line-item common stock balances reported as 202,942, 19,427, and 2,942 depending on the specific line items after the transactions.

Who signed the Form 4 for Amorelli Angelo?

The form is signed by E. Cabell Massey, Attorney-in-Fact with a signature date of 08/15/2025.